We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Blood Tests Can Detect Inflammatory Bowel Diseases Years before Diagnosis

By LabMedica International staff writers
Posted on 08 Nov 2023
Print article
Image: The researchers looked at several clinical tests up to 10 years before inflammatory bowel disease diagnosis (Photo courtesy of M. Cell Reports Medicine)
Image: The researchers looked at several clinical tests up to 10 years before inflammatory bowel disease diagnosis (Photo courtesy of M. Cell Reports Medicine)

Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are chronic conditions that lead to ongoing inflammation in the digestive tract. This results in discomfort and symptoms such as stomach pain and persistent diarrhea. Recognizing and managing these conditions early is crucial for better patient outcomes. Past assumptions held that most patients experienced symptoms approximately one year prior to being diagnosed. However, the presence of significant damage to the bowels at the time of diagnosis indicated that these diseases might have been developing for a much more extended period. Now, new research has revealed that certain signs of Crohn’s disease can be identified through blood tests up to eight years before its diagnosis, and signs of ulcerative colitis can be detected up to three years prior.

This research, carried out by investigators at the Francis Crick Institute (London, UK) and Aalborg University (Copenhagen, Denmark), highlights that the onset of inflammatory bowel diseases occurs well before symptoms manifest. This discovery opens the possibility for healthcare providers to intervene preemptively or to start treatment at an earlier, potentially more effective stage. The researchers reached their findings by reviewing ten years of blood test results leading up to an IBD diagnosis. They noted variations in specific blood minerals, cell counts, and inflammation indicators, including fecal calprotectin—a marker released during bowel inflammation and currently used to decide if a person with gastrointestinal complaints should undergo more detailed examinations. These variations became noticeable up to eight years before Crohn's disease was diagnosed and three years before ulcerative colitis was diagnosed.

What's particularly noteworthy is that many of these changes were minor and fell within what would be considered normal ranges in standard blood tests, meaning they wouldn't typically trigger alarms for further action. It took a comprehensive analysis of a large volume of data to spot these subtle changes among various indicators. The researchers aim to delve further, exploring whether initiating treatment or preventive measures before symptoms appear could be beneficial, and examining whether these research insights could help predict who might develop IBD in the future.

“Our research shows that the bowel damage we’re seeing at the point of diagnosis is just the tip of the iceberg. So many changes are subtly taking place in the body before the disease takes hold,” said James Lee, Group Leader of the Genetic Mechanisms of Disease Laboratory at the Crick. “This has huge implications for prevention as it highlights that there’s a window of opportunity for treatment.”

“Our findings are novel and go hand-in-hand with emerging evidence that chronic inflammatory bowel diseases likely have their onset years prior to diagnosis,” added Tine Jess, Director at the Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, at Aalborg University.

Related Links:
Francis Crick Institute
Aalborg University

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
POCT Fluorescent Immunoassay Analyzer
C. difficile Toxins Test

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.